Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Boston Scientific Corporation
First patient enrolled in trial for paclitaxel-eluting coronary stent system
September 24th, 2004
Boston Scientific Corporation (BSX) announced that enrollment has begun in its ATLAS clinical trial. ATLAS is the first trial using Boston Scientific's new Liberte coronary stent as a platform for its paclitaxel-eluting coronary stent system. Taxus Liberte will be the next generation to Boston Scientific's current paclitaxel-eluting coronary stent system, Taxus Express2. The Liberte stent, which has been designed to further enhance deliverability and conformability, particularly in challenging lesions, is currently available in international markets in a bare metal version. The ATLAS trial is a pivotal study to collect data to...
Source: Food & Drug Law Weekly (2004-09-24)
|
